Last reviewed · How we verify
Supportive care+Prednisone
Supportive care+Prednisone is a Corticosteroid + Supportive care Small molecule drug developed by Air Force Military Medical University, China. It is currently in Phase 3 development for Inflammatory or immune-mediated conditions requiring corticosteroid therapy (specific indication not publicly detailed). Also known as: Control group.
Prednisone suppresses immune and inflammatory responses through glucocorticoid receptor activation, while supportive care provides symptomatic relief and organ support.
Prednisone is a small molecule used in supportive care, as indicated by its use in various clinical trials for conditions such as Diffuse Large B Cell Lymphoma and HIV Infections. It is often used in combination with other treatments, including R-CHOP and Highly active antiretroviral therapy, for conditions such as Head and Neck Carcinoma and Oropharyngeal Carcinoma.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Immunology slight uplift
+1.0pp
Mature endpoint landscape (ACR, DAS28, PASI) makes immunology approvals slightly more predictable.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Supportive care+Prednisone |
|---|---|
| Also known as | Control group |
| Sponsor | Air Force Military Medical University, China |
| Drug class | Corticosteroid + Supportive care |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
Prednisone is a corticosteroid that binds to glucocorticoid receptors, reducing production of pro-inflammatory cytokines and suppressing T-cell and B-cell function. Supportive care encompasses symptomatic management, organ support, and general clinical interventions tailored to the patient's condition. Together, this combination addresses both the underlying inflammatory/immune pathology and clinical symptoms.
Approved indications
- Inflammatory or immune-mediated conditions requiring corticosteroid therapy (specific indication not publicly detailed)
Common side effects
- Hyperglycemia
- Hypertension
- Immunosuppression/increased infection risk
- Osteoporosis
- Mood disturbances
Key clinical trials
- Role of Gut Microbiome and Fecal Transplant on Medication-Induced GI Complications in Patients With Cancer (PHASE1)
- Split-Dose R-CHOP for Older Adults With DLBCL (PHASE2)
- High Dose Steroid Therapy (Prednisone or Methylprednisolone) for the Improvement of Symptoms of Late Radiation-Associated Lower Cranial Neuropathy in Oropharyngeal Cancer Survivors (PHASE1, PHASE2)
- Rituximab and Targeted Nursing for Pediatric Nephrotic Syndrome (NA)
- Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children (NA)
- Radium-223 Dichloride and Abiraterone Acetate Compared to Placebo and Abiraterone Acetate for Men With Cancer of the Prostate When Medical or Surgical Castration Does Not Work and When the Cancer Has Spread to the Bone, Has Not Been Treated With Chemotherapy and is Causing no or Only Mild Symptoms (PHASE3)
- Efficacy and Safety of Tacrolimus in Combination With Ripertamab in the Initial Treatment of Patients With MCD (PHASE3)
- Combination Chemotherapy & Lenalidomide in Newly Diagnosed Stage II-IV Peripheral T-cell Non-Hodgkin's Lymphoma (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Supportive care+Prednisone CI brief — competitive landscape report
- Supportive care+Prednisone updates RSS · CI watch RSS
- Air Force Military Medical University, China portfolio CI
Frequently asked questions about Supportive care+Prednisone
What is Supportive care+Prednisone?
How does Supportive care+Prednisone work?
What is Supportive care+Prednisone used for?
Who makes Supportive care+Prednisone?
Is Supportive care+Prednisone also known as anything else?
What drug class is Supportive care+Prednisone in?
What development phase is Supportive care+Prednisone in?
What are the side effects of Supportive care+Prednisone?
What does Supportive care+Prednisone target?
Related
- Drug class: All Corticosteroid + Supportive care drugs
- Target: All drugs targeting Glucocorticoid receptor
- Manufacturer: Air Force Military Medical University, China — full pipeline
- Therapeutic area: All drugs in Immunology
- Indication: Drugs for Inflammatory or immune-mediated conditions requiring corticosteroid therapy (specific indication not publicly detailed)
- Also known as: Control group
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing